Kintai Therapeutics launches to tackle the interface between the gut, immune system, and brain

The start-up, founded by Flagship Pioneering, is developing small-molecule drugs aimed at the gut microbiome, gut immune cells, and enteric nervous system

Source: Chemical and Engineering News - April 20, 2019 Category: Chemistry Authors: Ryan Cross Source Type: research